Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris(ITN059AI)
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Abatacept (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PAUSE
- 13 Oct 2021 Primary endpoint (The proportion of participants who experience a psoriasis relapse at any time between week 12 and week 88) has not been met according to the published in the JAMA Dermatology
- 13 Oct 2021 Results published in the JAMA Dermatology
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.